In essence, the higher the strength, the faster and greater your weight loss is expected to be, but thats not the only reason
The SELECT trial showed that semaglutide reduced major adverse cardiovascular events (heart attack, stroke, cardiovascular death) in adults with obesity and established cardiovascular disease, without requiring a diabetes diagnosis. The FLOW trial showed kidney benefits with semaglutide use in patients with type 2 diabetes and chronic kidney disease. Improvements in hard clinical outcomes like cardiac events, kidney disease, and death are commonly observed with GLP-1 use, and are due to both the direct effects of treating the obesity, and indirect effects of the medications themselves
In the SKYLIGHT 1 trial, which included 522 women, fezolinetant demonstrated efficacy in reducing hot flashes in menopausal and perimenopausal women, with a 58% and 61% decrease at a dosage of 30 mg and 45 mg, respectively, after 12 weeks of treatment
Several studies have examined how IDYs can contribute to wine composition and quality
Hypertens Res (2010) 33(5):44653
